

Notice of Allowability	Application No.	Applicant(s)	
	10/695,605	BROUGH ET AL.	
	Examiner David Guzo	Art Unit 1636	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to filing of the application on 10/28/03.
2. The allowed claim(s) is/are 1-15.
3. The drawings filed on _____ are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 10/28/03
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

Examiner's Comments

The following is an examiner's statement of reasons for allowance: The prior art does not teach or suggest the claimed human embryonic kidney cells comprising at least one heterologous nucleic acid sequence which encodes a non-adenoviral gene product which complements in *trans* for a deficiency in an adenoviral gene selected from E1, E4 and E2a as well as a method for propagating a replication deficient adenoviral vector using said cells. The closest prior art is exemplified by Bernards et al. (cited by applicants, Virology, 1986, Vol. 150, pp. 126-139) which discloses the possibility that one or more **endogenous** cellular proteins in human embryonic kidney cells (HEK) cells are functionally homologous to the adenoviral E1b 58kDa protein. No prior art teaches human embryonic kidney cells containing heterologous non-adenoviral gene sequences encoding the *trans* complementing proteins. While the prior art discloses cellular or non-adenoviral gene products which can complement various adenoviral functions including E1a, E1b, E4, E2a, etc. (see Spergel et al., J. Virology, 1992, Vol. 66, No. 2, pp. 1021-1030; Goldsmith et al., Virology, 1998, Vol. 248, pp. 406-419; Horvath et al., Virology, 1991, Vol. 184, pp. 141-148, etc., all cited by applicants), said art does not disclose or render obvious human embryonic kidney cells comprising heterologous genes encoding said non-adenoviral gene products. Additionally, the structural and functional motifs of the E1, E4 and E2a gene products are well known and additional non-adenoviral and cellular genes encoding products capable of complementing these adenoviral genes can easily be identified or synthesized.

Art Unit: 1636

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo, Ph.D., whose telephone number is (571) 272-0767. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, Ph.D., can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David Guzo
February 14, 2005



DAVID GUZO
PRIMARY EXAMINER